Top Markets
Coin of the day
Antisense Therapeutics Limited Antisense Therapeutics Limited

Antisense Therapeutics Limited

ANP
株式のランク #33635
Antisense Therapeutics Limited, an Australian company headquartered in Toorak... Antisense Therapeutics Limited, an Australian company headquartered in Toorak and founded in 2000, specializes in the research and advancement of innovative antisense pharmaceutical drugs. Its primary pipeline asset, ATL1102, is an antisense inhibitor designed to target CD49d, which is currently in Phase II clinical trials for treating various inflammatory conditions such as multiple sclerosis, Duchenne Muscular Dystrophy, and asthma. Another promising therapeutic in their portfolio is ATL1103, a second-generation antisense drug that aims to block growth hormone receptor expression, thereby lowering insulin-like growth factor-I levels in the blood, and has completed Phase II clinical trials for conditions stemming from excessive growth hormone action.
株価
$0.03702159
最終同期: 2024-01-29
時価総額
$7.21M
変化(1日)
-3.08%
変化(1年)
0.00%
AU
取引 Antisense Therapeutics Limited (ANP)

カテゴリー

Antisense Therapeutics Limited(ANP)の配当利回りの履歴
Antisense Therapeutics Limited(銘柄コード: ANP)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Antisense Therapeutics Limited(ANP)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)